Invention Grant
- Patent Title: Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease
-
Application No.: US13643210Application Date: 2011-04-26
-
Publication No.: US09266879B2Publication Date: 2016-02-23
- Inventor: Stephen Joseph Shuttleworth , Franck Alexandre Silva
- Applicant: Stephen Joseph Shuttleworth , Franck Alexandre Silva
- Applicant Address: GB Hampshire
- Assignee: Karus Therapeutic Limited
- Current Assignee: Karus Therapeutic Limited
- Current Assignee Address: GB Hampshire
- Agency: Goodwin Procter LLP
- Priority: GB1007347.6 20100430
- International Application: PCT/GB2011/050824 WO 20110426
- International Announcement: WO2011/135351 WO 20111103
- Main IPC: C07D471/04
- IPC: C07D471/04
Abstract:
Compounds of formulae (I) and (II): or a pharmaceutically acceptable salt thereof, wherein: R1 is a nitrogen-containing 5 to 7-membered heteroaryl or heterocycle; R2 and R3 are each independently (LQ)mY, are described. The compounds are PI3K inhibitors and are useful for the treatment of cancer and immune-inflammatory diseases.
Public/Granted literature
- US20130109688A1 Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease Public/Granted day:2013-05-02
Information query
